bioLytical Laboratories Applauds Researchers Involved In Landmark HIV/AIDS Study
Richmond, B.C., May 13, 2011 - Canadian life sciences firm bioLytical Laboratories is praising researchers who worked tirelessly on a landmark study whose findings scientists say could help stem the global AIDS pandemic.
The results of the HPTN 052, a randomized, phase 3 clinical trial, show that early HIV treatment not only benefits the person with HIV/AIDS, but also dramatically reduces the likelihood that he or she will transmit the virus to sexual partners.
Termed treatment as prevention this approach adds to the growing range of prevention and treatment options that, used in concert, many believe could help eradicate the disease, which has plagued the world for more than three decades.
bioLytical Chief Technical Officer Rick Galli says, "This combination of new and emerging HIV prevention methods provides us with hope that experts can dramatically constrict the flood of new infections. We're incredibly optimistic that bioLytical's INSTI Rapid HIV Antibody Test will play a significant role in the treatment as prevention approach and were excited to continue down this progressive path with other experts in the field."
The INSTI HIV Rapid Antibody Test is able to detect HIV antibodies in just 60 seconds or less. Ease of use and speed to result allow many more tests to be administered and people to find out their results almost instantaneously.
"It is estimated that up to 80% of the people infected with HIV in developing countries do not know they are infected. If those individuals were diagnosed, this would have a dramatic effect on slowing the spread of the disease," commented bioLytical Board Chairman Robert Mackie.
In 2009, 2.6 million people were newly infected with HIV, according to United Nations estimates. More than 33 million people are estimated to have HIV worldwide.
For more information, call bioLytical at 888-316-0351 or visit www.biolytical.com.
Laura Ballance Media Group